Exposing a Pepmoron the liar
Let me humiliate this lunatic moron, line by line!!!!
Roche and AstraZeneca were aware of FTS-Salirasib since the begining ofthe century.
Pepmoron is saying that Salirasib existed in 1900... It was discovered 10 years ago.
Farnesylthiosalycilic acid is an easily availablemolecule. So they made their own tests with it. They also know that4601 is very similar. So since all that time they were not interestedto strike any deal. So our Dumbo can dream of huge takeover scenario.
Pepmoron has the power to into Astra and Roche' intention. That's his claim. He also claimed that they made test on them out of pure fabrication
But based on the known facts. It seems that these farnesylated Rasinhibitor will have the same fate as the
Farnesyl transferaseinhibitors (FTis). These molecules are showing good activity inpre-clinical testing, but the results in human are not as good.Concordia "encouraging" results are a good proof of that. Nobreakthrough there. So forget the revolution in cancer treatment.
First of all, in Annual Information Return and since forever. Thallion said that 4601 is not a FTI. Also, Pepmoron dares trash clinical and validated positive results from Concordia!!!
Results that are publish at ASCO 2009!!! He dares call 'not good'.... Amazing.
That's why Concordia partnered with an OTC company insted of a big dealwith a big pharma, and that's why Thallion's stock priceis at 0.20$, and that's probably why the strategic review willtake more time. Thallion clearly needs to come up with results thatwill change the perception about farnesylated inhibitors. Until theycan provide these results it will remain very speculative.
This cretin goes on even after I even if he clearly knows that the info is contained in Annual info Return on page 15 (sedar)
TLN-4601 was evaluated on different types of human tumor cell lines for its ability to interfere with Ras
processing via protein prenylation by monitoring farnesyl transferase (FTase) and Geranylgeranyl
transferase (GGTase) I activities. Downstream Ras signaling events, such as Raf-1 and ERK1/2
phosphorylation, were also evaluated by immunoblots. No mobility shift of either HDJ2 or Rap1A
(surrogate markers of FTase and GGTase I, respectively) were observed in cells exposed to TLN-4601 for
up to 48h suggesting TLN-4601 does not inhibit Ras prenylation. In contrast, a strong inhibition of EGFinduced
phosphorylation of c-Raf-1 and ERK1/2 in mutated cancer cell lines tested was shown. This
effect was time-dependent with complete inhibition of protein phosphorylation within 6h. Recent data
indicate that TLN-4601 decreases Ras-GTP levels (active form of Ras) and total Raf-1 protein levels
leading to an inhibiton of MEK and ERK phosphorylation. Other studies showed that TLN-4601 does not
directly inhibit EGFR, c-Raf, MEK1, ERK1 or ERK2 kinase activities. Taken together, TLN-4601 is not
a FTase inhibitor and inhibits Ras signaling by inhibiting Ras activation and decreasing Raf-1 protein.
Further experiments are ongoing to establish the specific target(s)/mechanism by which these effects are
mediated.
Until theycan provide these results it will remain very speculative.
Yet we all know that Pepmoron has all his money in Methylgene a failed biotech, abandon by Celgene partner in favor of GlobeImmune - A RAS inhibitor...
Methylgene is a PI company, running out of option and cash.
According to Pepmoron, Methylgene is "flexible", low risk and safe!!!
Amazing!!!!